title: The failure of figitumumab: the danger of taking shortcuts in drug development.
authors.affiliation: Department of Medical Oncology, Swedish Cancer Institute, Seattle, USA howard.west@swedish.org.
authors.forename: H
authors.initials: H
authors.lastname: West
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000069347:Erlotinib Hydrochloride / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male
chemical_list: D000911:Antibodies, Monoclonal; D000069347:Erlotinib Hydrochloride